JPMorgan Chase & Co. Increases GSK (LON:GSK) Price Target to GBX 1,500

GSK (LON:GSK) had its price objective increased by equities researchers at JPMorgan Chase & Co. from GBX 1,400 to GBX 1,500 in a report released on Friday, Marketbeat.com reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential downside of 15.18% from the company’s previous close.

A number of other research firms also recently commented on GSK. Shore Capital reaffirmed a “buy” rating and set a GBX 2,100 target price on shares of GSK in a report on Monday, October 20th. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 1,600 price objective on shares of GSK in a report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,450 target price on shares of GSK in a report on Thursday, July 31st. Finally, Jefferies Financial Group upped their price target on shares of GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a report on Monday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of GBX 1,750.

GSK Stock Down 0.6%

Shares of GSK traded down GBX 10 during mid-day trading on Friday, hitting GBX 1,768.50. 7,021,667 shares of the company traded hands, compared to its average volume of 11,714,042. The company has a market capitalization of £71.08 billion, a PE ratio of 13.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The business has a 50 day moving average of GBX 1,584.45 and a 200 day moving average of GBX 1,480.94. GSK has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 1,799.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In other news, insider Wendy Becker acquired 526 shares of the business’s stock in a transaction on Friday, September 19th. The stock was bought at an average price of GBX 1,503 per share, with a total value of £7,905.78. Insiders have acquired a total of 576 shares of company stock worth $865,799 in the last quarter. 0.20% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.